Hydroxamate-based inhibitors of low affinity IgE receptor (CD23) processing

Abstract A series of hydroxamic acids related to the non-selective matrix metalloprotease inhibitor Batimastat is described, which inhibits the proteolytic cleavage of the low affinity IgE receptor from cell membrane preparations. Limited SAR studies suggest that the structural requirements for effective inhibition are distinct from those required for the inhibition of collagenase. We have examined the P 1′ requirements for hydroxamate based inhibitors of the novel metalloprotease responsible for processing of the low affinity IgE receptor (CD23).